Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morphine or Ketamine in Cardiac Arrest
NCT04009759Phase 1Not yet recruiting
- Start
- Oct 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, triple-blind trial of morphine and ketamine in cardiac arrest (SCA) (3 arms). Primary endpoint: Survival at 28 days in patients after in-hospital cardiac arrest. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
morphineketamine
03
Conditions
cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT04009759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04009759.